[Current status of erlotinib and gefitinib in palliative therapy for NSCLC--does the EGF-R mutation state have any significance?].

Wolfgang Brückl* (First author), G H Wiest, Joachim H. Ficker (Last author)

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Original languageGerman
Pages (from-to)727-735
JournalPNEUMOLOGIE
Volume64
Issue number12
DOIs
Publication statusPublished - 2010

Cite this